Table 6 Subgroup analyses
Available data | Number of responders | p-valuea | Number with disease control | p-valuea | |
|---|---|---|---|---|---|
n (%) | (CR + PR) | (CR + PR + SD) | |||
FcγRIIa polymorphism (N = 27) | 0.12 | 0.19 | |||
H/R | 13 (48) | 0 | 4 | ||
H/H | 7 (26) | 1 | 2 | ||
R/R | 7 (26) | 2 | 5 | ||
FcγRIIIa polymorphism (N = 32) | >0.99 | 0.72 | |||
V/F | 13 (41) | 2 | 6 | ||
F/F | 12 (38) | 1 | 4 | ||
V/V | 7 (22) | 1 | 2 | ||
DLBCL molecular subtype (N = 27) | 0.66 | >0.99 | |||
GCB | 14 (52) | 1 | 4 | ||
ABC | 11 (41) | 2 | 4 | ||
Other | 2 (7) | 0 | 1 | ||
CD40 staining intensity (N = 38) | 0.17 | 0.24 | |||
3+ | 22 (58) | 3 | 8 | ||
2+ | 13 (34) | 0 | 7 | ||
1+ | 2 (5) | 1 | 2 | ||
0 | 1 (3) | 0 | 0 | ||
CD40 expression (N = 38) | 0.45 | >0.99 | |||
≥2+ and ≥80% positive | 33 (87) | 3 | 15 | ||
<2+ OR <80% positive | 5 (13) | 1 | 2 | ||
Prior ASCT (N = 43) | 0.62 | 0.75 | |||
Yes | 16 (37) | 2 | 7 | ||
No | 27 (63) | 2 | 10 |